FDA lifts clinical hold on DiaMedica's DM199 acute ischemic stroke trial

DiaMedica Therapeutics Inc.

FDA removed clinical hold on IND for DM199 phase 2/3 ReMEDy2 trial in acute ischemic stroke.
Hold removal allows DiaMedica to proceed with enrollment and dosing in the trial.
Investor presentation summarizing the update made available on June 21, 2023.
No financial guidance or trial timeline details disclosed in the filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.